IP Library › Assignment 062318/0798
Patent Assignment
Reel/Frame 062318/0798

Assignment of Assignor's Interest

Recorded: 2023-01-09 Pages: 7
Assignor
VIRGINIA COMMONWEALTH UNIVERSITY
Executed: 2021-10-12
Assignees
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
810 VERMONT AVENUE, N.W., OFFICE OF GENERAL COUNSEL, WASHINGTON, DISTRICT OF COLUMBIA, 20420
VIRGINIA COMMONWEALTH UNIVERSITY
800 EAST LEIGH STREET, SUITE 3000, RICHMOND, VIRGINIA, 23298
Covered Properties (8)
Nuclear Sulfated Oxysterol, Potent Regulator of Cholesterol Homeostasis, for Therapy of Hypercholesterolemia, Hyperlipidemia, and Atherosclerosis
Application: 11/739,330 →
Publication: US 2007/0275939
Nuclear Sulfated Oxysterol, Potent Regulator of Lipid Homeostasis, for Therapy of Hypercholesterolemia, Hypertriglycerides, Fatty Liver Diseases, and Atherosclerosis
Patent: 8,399,441 →
Application: 12/708,803 →
Publication: US 2010/0273761
Nuclear Sulfated Oxysterol, Potent Regulator of Lipid Homeostasis, for Therapy of Hypercholesterolemia, Hypertriglycerides, Fatty Liver Diseases, and Atherosclerosis
Patent: 9,321,802 →
Application: 13/766,839 →
Publication: US 2013/0143854
Nuclear Sulfated Oxysterol, Potent Regulator of Lipid Homeostasis, for Therapy of Hypercholesterolemia, Hypertriglycerides, Fatty Liver Diseases, and Atherosclerosis
Application: 15/042,244 →
Publication: US 2016/0264615
Nuclear Sulfated Oxysterol, Potent Regulator of Lipid Homeostasis, for Therapy of Hypercholesterolemia, Hypertriglycerides, Fatty Liver Diseases, and Atherosclerosis
Application: 16/154,007 →
Publication: US 2019/0169225
Nuclear Sulfated Oxysterol, Potent Regulator of Lipid Homeostasis, for Therapy of Hypercholesterolemia, Hypertriglycerides, Fatty Liver Diseases, and Atherosclerosis
Application: 17/060,886 →
Publication: US 2021/0147469
Nuclear oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and antherosclerosis
Application: 60/621,537 →
5-Cholesten-3b, 25-diol 3-sulfate (25HC3S), an authentic PPARy agonist and LXR antagonist, for the therapy of inflammatory diseases, such as inflammatory bowel diseases, fat liver diseases, and atherosclerotic diseases
Application: 61/154,063 →
Related Assignments (7)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Jul 23, 2007
From: REN, SHULIN; PANDAK, WILLIAM N.
To: VIRGINIA COMMONWEALTH UNIVERSITY
Reel/Frame 019586/0780 →
Assignment of Assignor's Interest Jul 8, 2010
From: REN, SHUNLIN; PANDAK, WILLIAM M.
To: VIRGINIA COMMONWEALTH UNIVERSITY
Reel/Frame 024649/0895 →
Assignment of Assignor's Interest Feb 22, 2013
From: REN, SHUNLIN; PANDAK, WILLIAM M.
To: VIRGINIA COMMONWEALTH UNIVERSITY
Reel/Frame 029856/0706 →
Assignment of Assignor's Interest Feb 12, 2016
From: REN, SHUNLIN; PANDAK, WILLIAM M., JR.
To: VIRGINIA COMMONWEALTH UNIVERSITY
Reel/Frame 037722/0360 →
Assignment of Assignor's Interest Oct 8, 2018
From: REN, SHUNLIN; PANDAK, WILLIAM M.
To: VIRGINIA COMMONWEALTH UNIVERSITY
Reel/Frame 047091/0854 →
Assignment of Assignor's Interest Nov 11, 2019
From: REN, SHUNLIN; PANDAK, WILLIAM M.
To: VIRGINIA COMMONWEALTH UNIVERSITY
Reel/Frame 050970/0369 →
Assignment of Assignor's Interest Mar 16, 2021
From: REN, SHUNLIN; PANDAK, WILLIAM M.
To: VIRGINIA COMMONWEALTH UNIVERSITY
Reel/Frame 055611/0477 →